Navigation Links
Targeting leukemia cell's gene 'addiction' presents new strategy for treatment
Date:3/3/2010

An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells. The research, reported in EMBO Molecular Medicine, reveals how leukaemia cells become 'addicted' to genes, which if targeted could prevent diseased cells from developing.

The team, led by Dr Veronika Sexl from the University of Vienna, carried out their research on acute lymphoid leukaemia (ALL) and chronic myelogenous leukaemia (CML), which can both be caused by fusion protein, Bcr-Abl, created through the joining of two or more genes originally coded for separate proteins.

This joining of genes results in a complex tumor supporting 'network' which supports the growth and survival of the leukaemic cells. Inhibitor drugs such as 'Imatinib' can block vital signals and lead to leukemia cell death, but there are several mutations which can resist these inhibitors, making them ineffective.

As an alternative strategy the team investigated transcription factors Stat3 and Stat5 which are linked to bcr/abl-induced transformation. The team tested whether Stat3 and Stat5, acting downstream of Bcr-Abl are critical for leukaemia maintenance and if they could be a alternative target for treatment.

"We developed a tumour-specific gene-deletion approach to analyse the roles of Stat5 and Stat3 in Bcr/Abl-induced leukaemia growth," said Sexl. "We discovered that both factors are required for the development of Bcr-Abl, but once established only Stat5 is crucial for the survival and growth of leukemic Cells."

Even mutated forms of bcr-abl, Leukaemia cells, which are resistant to inhibiting drugs such as Imatinib, are still dependent on Stat5.

"Cancer cells undergo extensive adaptations in their signalling and metabolic pathways, thereby becoming dependent on certain genes," said Sexl. "In fact the activity of these genes can become limiting for a cancer cell."

The term 'Non-oncogene addication' (NOA) has been coined to describe this phenomenon of gene dependency and inhibiting these critical genes within the signalling network is predicted to cause system failure and halt the growth of leukaemia cells.

"In this study we demonstrated that bcr-abl, Leukaemia cells are addicted to Stat5 to maintain the leukameic state, concluded Sexl. "We've identified Stat5 as an Achilles' heel in the signalling network downstream of Bcr-Abl. Thus, inhibition of Stat5 may provide a novel therapeutic approach for treatment of leukaemia."


'/>"/>

Contact: Ben Norman
Lifesciencenews@wiley.com
44-124-377-0375
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche
2. Hacker Attacks Targeting Healthcare Organizations Doubled in the 4th Quarter of 2009 According to SecureWorks Data
3. Targeting cancerous vessels
4. Targeting brain cancer cell metabolism may provide new treatment
5. With White House Jobs Summit This Week KSBH Unveils New TV Ads Targeting Senators on Health Care
6. First live targeting of tumors with RNA-based technology
7. Wistar researchers show targeting normal cells in tumors slows growth
8. Success Targeting Competencies Missed in Traditional Testing Leads to Selection of Amistaff for Poster Presentations on Prophecy's Video-Based Situational Assessments
9. DNA test could be key to targeting treatments for head and neck cancer
10. Another Report Finds Swine Flu Targeting the Young
11. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... , ... June 20, 2017 , ... ... sites. To understand their regulatory principles, the research team developed expressRNA, a web ... RNA motif analyses. This reveals at nucleotide resolution the ‘RNA maps’, which demonstrate ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... industry has been selected as the partner of choice by Amtrak to fulfill ... service that provides medium- and long-distance intercity service in the contiguous United States. ...
(Date:6/20/2017)... ... June 20, 2017 , ... Uniworld Boutique River Cruise Collection ... line’s latest all-inclusive boutique ship, S.S. Joie de Vivre . What really sets ... cruising France’s Seine River and designed small enough to dock directly in Paris. With ...
(Date:6/20/2017)... ... 20, 2017 , ... The law firm of Momkus McCluskey Roberts LLC ... of the DuPage County Bar Association’s Board of Directors. Cassioppi officially took on the ... Drake in Oak Brook. Momkus McCluskey Roberts LLC attorney Stacey A. McCullough was also ...
(Date:6/19/2017)... ... June 19, 2017 , ... The joyful summer wedding season is ... a humdinger. A warm winter and wet spring have created ideal conditions for mosquitoes ... to be swatting away pesky mosquitoes when a bride and groom are saying their ...
Breaking Medicine News(10 mins):
(Date:6/5/2017)... The Cincinnati location of ... (NYSE: DPLO), has been awarded a Top Workplaces 2017 ... Results are based on an employee survey administered by WorkplaceDynamics, ... improvement. The survey measures several aspects of workplace culture, including ... ...
(Date:5/30/2017)... 30, 2017 DarioHealth Corp. (NASDAQ: DRIO), a leading global ... announced that it will be presenting at the 7th annual LD ... Erez Raphael , CEO, of DarioHealth will be giving the ... held on June 6th & 7th, 2017 at the Luxe Sunset ... / micro-cap space. About LD ...
(Date:5/26/2017)... BARBARA, Calif. , May 25, 2017  In ... United States , Direct Relief is working with ... overdose-reversing Naloxone available at no cost to community health ... other nonprofit providers nationwide. "Pfizer has ... access to medicines and ensuring patient safety through educational ...
Breaking Medicine Technology: